Indivior (LON:INDV) had its price target hoisted by equities research analysts at Jefferies Group from GBX 500 ($7.02) to GBX 610 ($8.56) in a note issued to investors on Monday. The brokerage currently has a “buy” rating on the specialty pharmaceutical company’s stock. Jefferies Group’s price objective suggests a potential upside of 55.22% from the company’s current price.
Other equities analysts have also recently issued reports about the stock. Numis Securities reissued a “buy” rating and issued a GBX 600 ($8.42) price objective on shares of Indivior in a research report on Friday, March 23rd. Royal Bank of Canada upped their price objective on shares of Indivior from GBX 500 ($7.02) to GBX 540 ($7.58) and gave the company an “outperform” rating in a research report on Friday, January 26th. Finally, Morgan Stanley upped their price objective on shares of Indivior from GBX 450 ($6.32) to GBX 455 ($6.39) and gave the company an “equal weight” rating in a research report on Tuesday, April 3rd. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. Indivior has a consensus rating of “Buy” and an average price target of GBX 515.83 ($7.24).
Shares of Indivior stock opened at GBX 393 ($5.52) on Monday. Indivior has a twelve month low of GBX 246.50 ($3.46) and a twelve month high of GBX 436.60 ($6.13).
Indivior Company Profile
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence worldwide. The company's product candidates focus on treating opioid use disorder, alcohol use disorder, overdose rescue, and CNS disorders/schizophrenia.
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.